GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Net Margin %

EV Biologics (EV Biologics) Net Margin % : -5.78% (As of Dec. 2017)


View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Net Margin %?

Net margin is calculated as Net Income divided by its Revenue. EV Biologics's Net Income for the three months ended in Dec. 2017 was $-2.24 Mil. EV Biologics's Revenue for the three months ended in Dec. 2017 was $38.72 Mil. Therefore, EV Biologics's net margin for the quarter that ended in Dec. 2017 was -5.78%.

The historical rank and industry rank for EV Biologics's Net Margin % or its related term are showing as below:


YECO's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -154.79
* Ranked among companies with meaningful Net Margin % only.

EV Biologics Net Margin % Historical Data

The historical data trend for EV Biologics's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Net Margin % Chart

EV Biologics Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17
Net Margin %
23.66 24.05 18.78 -124.73 -78.15

EV Biologics Quarterly Data
Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Jun17 Dec17
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,117.19 -101.25 -124.73 - -5.78

Competitive Comparison of EV Biologics's Net Margin %

For the Biotechnology subindustry, EV Biologics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EV Biologics's Net Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EV Biologics's Net Margin % distribution charts can be found below:

* The bar in red indicates where EV Biologics's Net Margin % falls into.



EV Biologics Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

EV Biologics's Net Margin for the fiscal year that ended in Jun. 2017 is calculated as

Net Margin=Net Income (A: Jun. 2017 )/Revenue (A: Jun. 2017 )
=-7.43/9.507
=-78.15 %

EV Biologics's Net Margin for the quarter that ended in Dec. 2017 is calculated as

Net Margin=Net Income (Q: Dec. 2017 )/Revenue (Q: Dec. 2017 )
=-2.239/38.723
=-5.78 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


EV Biologics  (OTCPK:YECO) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.


EV Biologics Net Margin % Related Terms

Thank you for viewing the detailed overview of EV Biologics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


EV Biologics (EV Biologics) Business Description

Traded in Other Exchanges
N/A
Address
1621 Central Avenue, Cheyenne, WY, USA, 82001
EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.
Executives
Daniel S Mckinney director, 10 percent owner, officer: CEO TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan director C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3

EV Biologics (EV Biologics) Headlines

From GuruFocus

EV Biologics Updates Shareholders on Name and Symbol Change

By ACCESSWIRE ACCESSWIRE 05-19-2021

EV Biologics Updates on FINRA

By ACCESSWIRE ACCESSWIRE 01-18-2022

EV Biologics is now Pink Current

By ACCESSWIRE ACCESSWIRE 06-14-2021

EV Biologics Signs LOI with Lonza Cell & Gene Therapy

By ACCESSWIRE ACCESSWIRE 07-22-2021

EV Biologics Signs Listing Agreement With INX

By ACCESSWIRE ACCESSWIRE 11-11-2021

EV Biologics NFT Dividend Information

By ACCESSWIRE ACCESSWIRE 08-09-2021

EV Biologics Updates on NFT Dividend

By ACCESSWIRE ACCESSWIRE 11-12-2021

EV Biologics Generates Mesenchymal Stem Cell Lines

By ACCESSWIRE ACCESSWIRE 02-21-2023